| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CONTROVERSY IN CLINICAL ENDOCRINOLOGY |
Department of Medicine, Washington Hospital Center, Washington, D.C. 20010; Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814; and Georgetown University School of Medicine, Washington, D.C. 20006
Address all correspondence and requests for reprints to: Dr. Leonard Wartofsky, Department of Medicine, Washington Hospital Center, 110 Irving Street NW, Washington, D.C. 20010-2975. E-mail: leonard.wartofsky{at}medstar.net.
Debate and controversy currently surround the recommendations of a recent consensus conference that considered issues related to the management of early, mild, or so-called subclinical hypothyroidism and hyperthyroidism. Intimately related to the controversy is the definition of the normal reference range for TSH. It has become clear that previously accepted reference ranges are no longer valid as a result of both the development of more highly sensitive TSH assays and the appreciation that reference populations previously considered normal were contaminated with individuals with various degrees of thyroid dysfunction that served to increase mean TSH levels for the group. Recent laboratory guidelines from the National Academy of Clinical Biochemistry indicate that more than 95% of normal individuals have TSH levels below 2.5 mU/liter. The remainder with higher values are outliers, most of whom are likely to have underlying Hashimoto thyroiditis or other causes of elevated TSH. Importantly, data indicating that African-Americans with very low incidence of Hashimoto thyroiditis have a mean TSH level of 1.18 mU/liter strongly suggest that this value is the true normal mean for a normal population. Recognition and establishment of a more precise and true normal range for TSH have important implications for both screening and treatment of thyroid disease in general and subclinical thyroid disease in particular.
This article has been cited by other articles:
 |
|
 |
|
  H. Volzke, D. M. Robinson, T. Spielhagen, M. Nauck, A. Obst, R. Ewert, B. Wolff, H. Wallaschofski, S. B. Felix, and M. Dorr Are serum thyrotropin levels within the reference range associated with endothelial function? Eur. Heart J., November 13, 2008; (2008) ehn508v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Heeringa, E. H. Hoogendoorn, W. M. van der Deure, A. Hofman, R. P. Peeters, W. C. J. Hop, M. den Heijer, T. J. Visser, and J. C. M. Witteman High-Normal Thyroid Function and Risk of Atrial Fibrillation: The Rotterdam Study Arch Intern Med, November 10, 2008; 168(20): 2219 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. A. Strieder, J. G. P. Tijssen, B. E. Wenzel, E. Endert, and W. M. Wiersinga Prediction of Progression to Overt Hypothyroidism or Hyperthyroidism in Female Relatives of Patients With Autoimmune Thyroid Disease Using the Thyroid Events Amsterdam (THEA) Score Arch Intern Med, August 11, 2008; 168(15): 1657 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Hamilton, S. Davis, L. Onstad, and K. J. Kopecky Thyrotropin Levels in a Population with No Clinical, Autoantibody, or Ultrasonographic Evidence of Thyroid Disease: Implications for the Diagnosis of Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1224 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Biondi and D. S. Cooper The Clinical Significance of Subclinical Thyroid Dysfunction Endocr. Rev., February 1, 2008; 29(1): 76 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Surks and J. G. Hollowell Age-Specific Distribution of Serum Thyrotropin and Antithyroid Antibodies in the U.S. Population: Implications for the Prevalence of Subclinical Hypothyroidism J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4575 - 4582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Spencer, J. G. Hollowell, M. Kazarosyan, and L. E. Braverman National Health and Nutrition Examination Survey III Thyroid-Stimulating Hormone (TSH)-Thyroperoxidase Antibody Relationships Demonstrate That TSH Upper Reference Limits May Be Skewed by Occult Thyroid Dysfunction J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4236 - 4240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Casey and K. J. Leveno Thyroid disease in pregnancy. Obstet. Gynecol., November 1, 2006; 108(5): 1283 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Walsh, L. C. Ward, V. Burke, C. I. Bhagat, L. Shiels, D. Henley, M. J. Gillett, R. Gilbert, M. Tanner, and B. G. A. Stuckey Small Changes in Thyroxine Dosage Do Not Produce Measurable Changes in Hypothyroid Symptoms, Well-Being, or Quality of Life: Results of a Double-Blind, Randomized Clinical Trial J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2624 - 2630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Teng, Z. Shan, X. Teng, H. Guan, Y. Li, D. Teng, Y. Jin, X. Yu, C. Fan, W. Chong, et al. Effect of iodine intake on thyroid diseases in China. N. Engl. J. Med., June 29, 2006; 354(26): 2783 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Brabant, P Beck-Peccoz, B Jarzab, P Laurberg, J Orgiazzi, I Szabolcs, A P Weetman, and W M Wiersinga Is there a need to redefine the upper normal limit of TSH? Eur. J. Endocrinol., May 1, 2006; 154(5): 633 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Giavarina, R. M. Dorizzi, and G. Soffiati Indirect Methods for Reference Intervals Based on Current Data Clin. Chem., February 1, 2006; 52(2): 335 - 337. [Full Text] [PDF]
|
|
|
|
|
|
E. Grossi, R. Colombo, S. Cavuto, and C. Franzini Indirect Methods for Reference Intervals Based on Current Data: The authors of the article cited above respond: Clin. Chem., February 1, 2006; 52(2): 337 - 338. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
